Display options
Cite
Abdel-Wahab R, Shehata S, Hassan MM, et al. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015;2:131-42doi: 10.2147/JHC.S81309.
Abdel-Wahab, R., Shehata, S., Hassan, M. M., Habra, M. A., Eskandari, G., Tinkey, P. T., Mitchell, J., Lee, J. S., Amin, H. M., & Kaseb, A. O. (2015). Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. Journal of hepatocellular carcinoma, 2131-42. https://doi.org/10.2147/JHC.S81309
Abdel-Wahab, Reham, et al. "Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma." Journal of hepatocellular carcinoma vol. 2 (2015): 131-42. doi: https://doi.org/10.2147/JHC.S81309
Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015 Sep 18;2:131-42. doi: 10.2147/JHC.S81309. eCollection 2015. PMID: 27508202; PMCID: PMC4918293.
Copy Download .nbib Format: NLM
Share it on

J Hepatocell Carcinoma. 2015 Sep 18;2:131-42. doi: 10.2147/JHC.S81309. eCollection 2015.

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma.

Journal of hepatocellular carcinoma

Reham Abdel-Wahab, Samir Shehata, Manal M Hassan, Mouhammed A Habra, Ghazaleh Eskandari, Peggy T Tinkey, Jennifer Mitchell, Ju-Seog Lee, Hesham M Amin, Ahmed O Kaseb

Affiliations

  1. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt.
  2. Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt.
  3. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  4. Department of Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  5. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  6. Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  7. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  8. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate School of Biomedical Sciences, Houston, TX, USA.

PMID: 27508202 PMCID: PMC4918293 DOI: 10.2147/JHC.S81309

Abstract

Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child-Turcotte-Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials.

Keywords: IGF-I; chronic liver disease; growth hormone

References

  1. PLoS One. 2014 Mar 04;9(3):e90862 - PubMed
  2. Endocr Rev. 2001 Dec;22(6):800-17 - PubMed
  3. Int J Cancer. 2003 Dec 20;107(6):873-7 - PubMed
  4. J Mol Endocrinol. 1998 Oct;21(2):97-107 - PubMed
  5. Annu Rev Physiol. 1985;47:443-67 - PubMed
  6. Growth Horm IGF Res. 2006 Oct-Dec;16(5-6):277-89 - PubMed
  7. J Natl Cancer Inst. 2014 May 09;106(5):null - PubMed
  8. J Hepatol. 2002 Jun;36(6):751-8 - PubMed
  9. Ann Oncol. 2012 Oct;23 Suppl 7:vii41-8 - PubMed
  10. Science. 1983 Apr 1;220(4592):77-9 - PubMed
  11. J Clin Oncol. 2011 Oct 10;29(29):3892-9 - PubMed
  12. Endocr Rev. 2009 Aug;30(5):494-535 - PubMed
  13. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19378-83 - PubMed
  14. Endocrinology. 1997 Nov;138(11):4683-9 - PubMed
  15. Endocr Relat Cancer. 2012 Sep 14;19(5):625-44 - PubMed
  16. Endocrinol Metab Clin North Am. 2012 Jun;41(2):425-43, vii-viii - PubMed
  17. Am J Physiol. 1997 Jun;272(6 Pt 1):E1108-16 - PubMed
  18. Semin Liver Dis. 1999;19(3):329-38 - PubMed
  19. Metabolism. 2003 Aug;52(8):964-9 - PubMed
  20. J Hepatol. 1999 Jul;31(1):133-41 - PubMed
  21. Endocr Regul. 1999 Jun;33(2):90-4 - PubMed
  22. J Clin Endocrinol Metab. 1997 Mar;82(3):861-4 - PubMed
  23. J Endocrinol. 1989 Sep;122(3):611-8 - PubMed
  24. J Clin Endocrinol Metab. 1993 Apr;76(4):996-1001 - PubMed
  25. J Clin Endocrinol Metab. 1985 Jul;61(1):152-9 - PubMed
  26. N Engl J Med. 1969 Jun 26;280(26):1434-8 - PubMed
  27. J Gastroenterol. 2003;38(3):207-15 - PubMed
  28. J Clin Endocrinol Metab. 1998 May;83(5):1662-7 - PubMed
  29. Endocr J. 1999 Mar;46 Suppl:S59-62 - PubMed
  30. Endocr Rev. 1989 Feb;10(1):68-91 - PubMed
  31. Adv Cancer Res. 1996;68:183-223 - PubMed
  32. J Clin Endocrinol Metab. 2011 Oct;96(10 ):E1640-4 - PubMed
  33. J Hepatol. 1993 Mar;17(3):315-20 - PubMed
  34. Liver Int. 2011 Aug;31(7):911-9 - PubMed
  35. Nat Rev Cancer. 2002 Aug;2(8):563-72 - PubMed
  36. Mol Carcinog. 2000 Jan;27(1):10-7 - PubMed
  37. Br J Cancer. 2001 May 18;84(10 ):1322-9 - PubMed
  38. J Clin Invest. 1993 Feb;91(2):391-6 - PubMed
  39. Horm Res. 2003;60(2):53-60 - PubMed
  40. Clin Endocrinol (Oxf). 2010 May;72(5):625-32 - PubMed
  41. Ann Transplant. 2013 Feb 12;18:57-62 - PubMed
  42. J Clin Oncol. 2009 Jan 10;27(2):165-7 - PubMed
  43. Nutrition. 1997 Mar;13(3):185-90 - PubMed
  44. J Clin Endocrinol Metab. 1988 Jan;66(1):3-9 - PubMed
  45. Endocr Rev. 2004 Oct;25(5):693-721 - PubMed
  46. Cancer Lett. 2003 Jun 10;195(2):127-37 - PubMed
  47. J Clin Endocrinol Metab. 1997 Apr;82(4):1210-9 - PubMed
  48. J Clin Endocrinol Metab. 1996 Jun;81(6):2250-6 - PubMed
  49. J Clin Endocrinol Metab. 1993 Jun;76(6):1610-6 - PubMed
  50. J Clin Oncol. 2010 Sep 1;28(25):3994-4005 - PubMed
  51. J Clin Invest. 1997 Feb 15;99(4):643-50 - PubMed
  52. J Clin Endocrinol Metab. 2012 Jun;97(6):E907-16 - PubMed
  53. Endocrinology. 1999 Dec;140(12 ):5729-35 - PubMed
  54. Hepatogastroenterology. 2003 May-Jun;50(51):814-6 - PubMed
  55. World J Gastroenterol. 2004 Sep 15;10(18):2740-3 - PubMed
  56. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  57. J Clin Oncol. 2010 Nov 20;28(33):4985-95 - PubMed
  58. Cancer. 2002 Dec 15;95(12):2539-45 - PubMed
  59. Dig Dis Sci. 2007 Nov;52(11):3245-50 - PubMed
  60. Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):639-57 - PubMed
  61. Endocr Rev. 2007 Feb;28(1):20-47 - PubMed
  62. Trends Biochem Sci. 1990 Jul;15(7):265-70 - PubMed
  63. J Transl Med. 2012 Nov 14;10:224 - PubMed
  64. Cancer Res. 1999 Aug 15;59(16):3915-8 - PubMed
  65. Neuroendocrinology. 2003 Jun;77(6):380-7 - PubMed
  66. J Clin Invest. 1988 Apr;81(4):968-75 - PubMed
  67. Hepatology. 1997 Jul;26(1):81-9 - PubMed
  68. Arch Pharm Res. 2004 Apr;27(4):361-70 - PubMed
  69. Endocrinology. 1983 Jul;113(1):297-305 - PubMed
  70. J Clin Endocrinol Metab. 1987 Apr;64(4):651-6 - PubMed
  71. Acta Endocrinol (Copenh). 1977 Oct;86(2):355-62 - PubMed
  72. J Clin Endocrinol Metab. 1985 Feb;60(2):290-3 - PubMed
  73. Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E266-71 - PubMed
  74. Oncology. 2011;80(5-6):373-81 - PubMed
  75. J Clin Lab Anal. 2010;24(3):195-200 - PubMed
  76. Int J Cancer. 2000 Jul 1;87(1):118-21 - PubMed
  77. Endocr Rev. 1995 Apr;16(2):143-63 - PubMed
  78. Acta Endocrinol (Copenh). 1989 Jun;120(6):724-8 - PubMed
  79. Mol Cell Endocrinol. 1994 May;101(1-2):R1-14 - PubMed
  80. Metabolism. 1963 Jul;12:577-9 - PubMed
  81. Eur J Endocrinol. 2005 Oct;153(4):577-86 - PubMed
  82. Clin Endocrinol Metab. 1986 Feb;15(1):59-77 - PubMed
  83. Eur J Endocrinol. 2009 Nov;161(5):705-13 - PubMed
  84. Gut. 2005 Mar;54(3):419-25 - PubMed
  85. J Endocrinol. 2005 Mar;184(3):543-53 - PubMed
  86. Acta Endocrinol (Copenh). 1990 Sep;123(3):257-62 - PubMed
  87. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  88. Eur J Endocrinol. 1996 Aug;135(2):211-5 - PubMed
  89. J Biol Chem. 2002 Oct 11;277(41):38205-11 - PubMed
  90. Asian Pac J Cancer Prev. 2015;16(2):613-9 - PubMed
  91. Endocrinology. 1990 Jul;127(1):1-4 - PubMed
  92. Adv Exp Med Biol. 1993;343:105-12 - PubMed
  93. Acta Endocrinol (Copenh). 1989 Apr;120(4):442-6 - PubMed
  94. Clin Endocrinol (Oxf). 1995 Sep;43(3):265-75 - PubMed
  95. Bull World Health Organ. 1977;55(4):521-40 - PubMed
  96. Trends Endocrinol Metab. 2005 Nov;16(9):436-42 - PubMed
  97. EMBO J. 1998 Sep 1;17(17):5085-94 - PubMed
  98. J Clin Endocrinol Metab. 2005 Jul;90(7):3897-903 - PubMed
  99. Exp Clin Transplant. 2012 Jun;10(3):252-7 - PubMed
  100. J Clin Endocrinol Metab. 1997 Jul;82(7):2177-81 - PubMed
  101. Eur J Endocrinol. 1995 Jan;132(1):12-24 - PubMed
  102. Br J Cancer. 2000 Jan;82(2):385-91 - PubMed
  103. J Clin Endocrinol Metab. 1991 Feb;72(2):374-81 - PubMed
  104. Endocr Rev. 1995 Feb;16(1):3-34 - PubMed
  105. Crit Rev Clin Lab Sci. 2011 May-Jun;48(3):97-113 - PubMed
  106. J Lab Clin Med. 1957 Jun;49(6):825-36 - PubMed
  107. Am J Gastroenterol. 1993 Oct;88(10):1744-8 - PubMed
  108. J Musculoskelet Neuronal Interact. 2007 Jul-Sep;7(3):208-18 - PubMed
  109. Endocrinology. 1999 Apr;140(4):1657-64 - PubMed
  110. J Hepatol. 1997 Nov;27(5):796-802 - PubMed
  111. Hepatogastroenterology. 2011 May-Jun;58(107-108):949-54 - PubMed
  112. Liver Int. 2011 Jan;31(1):132-7 - PubMed
  113. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 - PubMed
  114. J Clin Endocrinol Metab. 1993 Jun;76(6):1407-12 - PubMed
  115. Arch Physiol Biochem. 2008 Feb;114(1):17-22 - PubMed
  116. Arch Intern Med. 1979 Oct;139(10):1157-60 - PubMed
  117. Trends Endocrinol Metab. 1994 Sep;5(7):296-303 - PubMed
  118. Biochemistry. 2001 Sep 18;40(37):11022-9 - PubMed
  119. Clin Biochem. 2006 Jun;39(6):623-9 - PubMed
  120. J Pediatr Endocrinol Metab. 1995 Apr-Jun;8(2):111-6 - PubMed
  121. Am J Dis Child. 1986 Feb;140(2):124-7 - PubMed
  122. Exp Clin Endocrinol Diabetes. 2002 Apr;110(2):67-73 - PubMed
  123. J Clin Endocrinol Metab. 2005 Apr;90(4):1953-60 - PubMed
  124. J Hepatol. 2008 Jul;49(1):34-42 - PubMed
  125. J Clin Endocrinol Metab. 2009 Oct;94(10):3931-8 - PubMed
  126. Hepatology. 1998 Sep;28(3):751-5 - PubMed
  127. Endocr Rev. 1992 May;13(2):281-98 - PubMed
  128. Clin Lung Cancer. 2012 Jan;13(1):68-74 - PubMed
  129. Cancer. 2002 Mar 15;94(6):1760-9 - PubMed
  130. HPB (Oxford). 2005;7(1):35-41 - PubMed
  131. Curr Diabetes Rev. 2011 Jul;7(4):235-45 - PubMed
  132. HPB (Oxford). 2010 Jun;12(5):300-1 - PubMed
  133. Dig Dis Sci. 1998 Jun;43(6):1317-21 - PubMed
  134. Cancer. 1985 Aug 15;56(4):918-28 - PubMed
  135. J Clin Invest. 1984 May;73(5):1425-33 - PubMed
  136. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  137. Annu Rev Physiol. 2001;63:141-64 - PubMed
  138. Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E967-76 - PubMed
  139. Science. 1981 Jun 12;212(4500):1279-81 - PubMed
  140. Ann Hepatol. 2013 May-Jun;12(3):456-63 - PubMed
  141. J Natl Cancer Inst. 2008 May 21;100(10):698-711 - PubMed
  142. Hepatology. 1990 Jan;11(1):123-6 - PubMed
  143. Oncol Rep. 2011 Aug;26(2):487-93 - PubMed
  144. J Clin Endocrinol Metab. 2011 Oct;96(10):E1619-29 - PubMed

Publication Types

Grant support